

**Division of Regulatory Operations for Cardiology, Hematology,  
Endocrinology, and Nephrology**

**REGULATORY PROJECT MANAGER LABELING REVIEW**

**Application:** NDA 213072/Supplement 004

**Name of Drug:** Roszet (rosuvastatin and ezetimibe) tablets

**Applicant:** Althera Pharmaceuticals, LLC.

**Labeling Reviewed**

**Submission Date:** October 26, 2023

**Receipt Date:** October 26, 2023

**Background and Summary Description:**

Roszet (rosuvastatin and ezetimibe) tablets is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated in adults:

- As an adjunct to diet in patients with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).
- Alone or as an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.

The original new drug application (NDA) was approved on March 23, 2021, with the following postmarketing requirement (PMR) listed in the approval letter.

4041-1            Conduct a study to collect efficacy and safety data pertaining to the use of ezetimibe with rosuvastatin in pediatric patients with homozygous familial hypercholesterolemia aged 2 to 17 years. Collect pharmacokinetic data as part of this study in pediatric patients younger than 8 years of age.

On November 10, 2022, we notified the Applicant they were released from PMR 4041-1, based on the prevalence of the condition, it is unlikely HoFH patients under the age of 8 would be treated by Roszet, and therefore, pharmacokinetic data in this age range need not be collected.

PMR 4041-1 was replaced with the following on November 10, 2022.

4041-2            Conduct a study to collect efficacy and safety data pertaining to the use of ezetimibe with rosuvastatin in pediatric patients with homozygous familial

hypercholesterolemia aged 2 to 17 years.

Final Protocol Submission: December 2022

Study Completion: March 2023

Final Report Submission: June 2023

The prior approval NDA 213072/S-004 efficacy supplement was submitted to address PMR 4041-2 proposing revisions for the Roszet Prescribing Information (PI) to include information on the use of rosuvastatin and ezetimibe combination therapy in pediatric patients with homozygous familial hypercholesterolemia. In addition, the Roszet PI was updated to be consistent with the Zetia (Approved July 2023) and the Crestor PI (Approved July 2023).

### Review

This project manager compared the labeling submitted on August 22, 2024, to the currently approved version, approved on March 23, 2021, using the MS Word electronic comparison function. A copy of this comparison document is appended to this review.

The following high-level changes were made to the PI and Patient Package Insert (PPI):

- Revisions were made to Sections 2.1 *Dosage and Administration Information* and 2.4 *Dosage Modifications Due to Drug Interactions* to be consistent with the listed drugs.
- Revisions were made to Sections 5.0 *Warnings and Precaution* to be consistent with the listed drugs.
- Revisions were made to Sections 6.0 *Adverse Reactions* to be consistent with the listed drugs.
- Modified Table 5 in Section 7.1 *Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with ROSZET* to include drug interaction information.
- Revisions were made to Section 8 *Use in Specific Populations* to be consistent with the listed drugs.
- Updated America's Poison Centers in Section 10 *Overdosage* to current name that removes the term "control."
- Revisions were made to Section 12 *Clinical Pharmacology* to be consistent with the listed drugs.
- Revised the PPI for consistency with the full PI. Additional revisions were made to reduce redundancy, to make patient information more consistent and concise, and to include the information necessary for patients to safely take their medication.

For a full list of recommendations, please see the following reviews in DARRTS:

- Clinical Review dated July 29, 2024 (Mary Roberts, MD, Clinical Reviewer, Eileen Craig, MD, Team Leader)

- Division of Medical Policy Programs (DMPP) Review dated June 13, 2024 (Kelly Jackson, PharmD, Patient Labeling Reviewer, Lashawn Griffiths, MSHS-PH, DSH, RN, Associate Director for Patient Labeling, and Marcia Williams, PhD, Team Leader, Patient Labeling)
- Office of Prescription Drug Promotion (OPDP) Review dated June 5, 2024 (Ankur Kalola, PharmD, Regulatory Review Officer)

### **Recommendations**

The labeling was reviewed by Drs. Eileen Craig, Mary Roberts, Monika Houston, and Melinda Wilson and found acceptable. The supplement is ready for approval. The Agency will issue an approval letter for this supplement.

Martin White	
Regulatory Project Manager	Date
Liz Solomon	8/23/2024
Chief, Project Management Staff	Date

33 Pages of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

MARTIN L WHITE  
08/26/2024 10:05:50 AM